Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma.
Jonas S HeitmannJuliane S WalzMartin PflüglerJoseph KauerRichard F SchlenkGundram JungHelmut R SalihPublished in: BMJ open (2020)
ClinicalTrials.gov Registry (NCT04104607) and ClinicalTrials.eu Registry (EudraCT2019-000238-20).